Assenagon Asset Management S.A. Purchases 109,284 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Assenagon Asset Management increased its IQVIA stake by 47.3% in the second quarter, adding 109,284 shares to own 340,476 shares valued at approximately $65.8 million. Institutional investors collectively hold 89.62% of IQVIA’s stock.
• IQVIA reported quarterly EPS of $3.15, beating estimates of $3.03, while revenue rose 8.7% year over year to $4.37 billion. The company also authorized a $2 billion share-repurchase program covering up to 6.8% of outstanding shares.
• Analysts remain broadly bullish, with a consensus “Moderate Buy” rating and an average price target of $241.88; several firms recently raised targets to between $276 and $288. IQVIA shares opened at $237.97, while insiders have sold 12,913 shares worth about $3.1 million over the past 90 days.

Assenagon Asset Management S.A. raised its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 47.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 340,476 shares of the medical research company's stock after acquiring an additional 109,284 shares during the period. Assenagon Asset Management S.A. owned about 0.20% of IQVIA worth $65,787,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Boston Partners acquired a new stake in IQVIA in the 3rd quarter valued at approximately $676,698,000. Norges Bank bought a new stake in IQVIA during the fourth quarter worth $497,445,000. Victory Capital Management Inc. lifted its stake in IQVIA by 2,628.1% in the fourth quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company's stock valued at $377,670,000 after acquiring an additional 1,614,063 shares during the last quarter. Orbis Allan Gray Ltd grew its position in shares of IQVIA by 96.5% in the 4th quarter. Orbis Allan Gray Ltd now owns 1,901,091 shares of the medical research company's stock valued at $428,525,000 after acquiring an additional 933,554 shares during the period. Finally, AQR Capital Management LLC increased its stake in shares of IQVIA by 130.2% during the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company's stock worth $245,099,000 after purchasing an additional 879,701 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Stock Up 2.4%

IQV opened at $237.97 on Friday. IQVIA Holdings Inc. has a one year low of $154.50 and a one year high of $251.36. The company has a fifty day moving average price of $200.92 and a 200-day moving average price of $186.95. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. The firm has a market capitalization of $39.17 billion, a P/E ratio of 29.53, a price-to-earnings-growth ratio of 1.97 and a beta of 1.18.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company had revenue of $4.37 billion for the quarter, compared to analysts' expectations of $4.30 billion. During the same period last year, the firm earned $2.81 earnings per share. IQVIA's quarterly revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities research analysts expect that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA announced that its board has approved a share repurchase plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company's board believes its stock is undervalued.

Analyst Ratings Changes

Several research analysts have recently commented on IQV shares. Stifel Nicolaus lifted their target price on IQVIA from $220.00 to $276.00 and gave the stock a "buy" rating in a research note on Wednesday, July 29th. JPMorgan Chase & Co. increased their target price on shares of IQVIA from $225.00 to $285.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 29th. TD Cowen raised their price objective on IQVIA from $233.00 to $288.00 and gave the stock a "buy" rating in a research note on Wednesday, July 29th. William Blair upgraded IQVIA to a "strong-buy" rating in a research report on Tuesday, July 28th. Finally, Weiss Ratings raised IQVIA from a "hold (c-)" rating to a "hold (c)" rating in a research note on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $241.88.

Insiders Place Their Bets

In related news, insider W Richard Staub sold 5,500 shares of IQVIA stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $232.68, for a total value of $1,279,740.00. Following the completion of the sale, the insider directly owned 13,312 shares in the company, valued at $3,097,436.16. The trade was a 29.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Bhavik Patel sold 1,855 shares of the company's stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $235.27, for a total transaction of $436,425.85. Following the completion of the sale, the insider directly owned 1,348 shares of the company's stock, valued at approximately $317,143.96. This trade represents a 57.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 12,913 shares of company stock worth $3,098,793 in the last 90 days. 1.70% of the stock is owned by insiders.

IQVIA Company Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source